摘要
目的探讨序贯过继免疫细胞联合长春瑞滨(N)和顺铂(P)方案化疗,同步放疗在非小细胞肺癌中的治疗效果。方法选择海南省人民医院收治的60例非小细胞肺癌患者作为研究对象,分为对照组和观察组,对照组采用NP方案化疗加同步放疗治疗。观察组在对照组基础上加用过继免疫细胞治疗。比较两组治疗效果、治疗前后免疫指标改善情况、生活质量改善情况及不良反应发生情况。结果观察组总有效率、临床受益率显著高于对照组,观察组治疗后各免疫指标改善情况显著优于对照组,观察组治疗后生活质量Karnofsky评分显著优于对照组,差异均有统计学意义(P<0.05);两组不良反应发生率差异无统计学意义(P>0.05)。结论序贯过继免疫细胞联合NP方案化疗、同步放疗治疗非小细胞肺癌临床效果显著,免疫功能改善明显,值得临床推广应用。
Objective To study the clinical effect of sequential adoptive immunity cells combined with chemo‐therapy of vinorelbine(N) and cis-platinum(P) and synchronous radiotherapy in the treatment of non‐small cell lung cancer(NSCLC) .Methods 60 patients with NSCLC were selected as the research subjects and randomly divided into the control group and the observation group .The control group adopted the NP chemotherapy+ synchronous radio‐therapy .On this basis the observation group was added with the adoptive immune cells therapy .The treatment effect , improvement of immune indexes before and after treatment ,improvement of the quality of life and occurrence situa‐tion of adverse reactions were observed and compared between the two groups .Results The total effective rate and clinical benefit rate of the observation group were significantly higher than those of the control group ,the improve‐ment situation of various immune indexes in the observation group were significantly superior to those in the control group ,the life quality Karnofsky score after treatent in the observation group were significantly better than those in the control group ,the differences were statistically significant(P〈 0 .05);the incidence of adverse reactions had no statistically significant difference between the two groups (P〉0 .05) .Conclusion Sequential adoptive immune cells combined with NP chemotherapy and radiotherapy has remarkable clinical effect for treating NSCLC ,the immune function is obviously improved ,which is worth clinical promotion and application .
出处
《检验医学与临床》
CAS
2015年第9期1235-1237,共3页
Laboratory Medicine and Clinic
关键词
过继免疫细胞
长春瑞滨
顺铂
化疗
同步放疗
非小细胞肺癌
adoptive immunity cells
vinorelbine
cisplatinum
chemotherapy
synchronous radiotherapy
non-small cell lung cancer